<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859287</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-GJP-DUM-2007/1</org_study_id>
    <nct_id>NCT00859287</nct_id>
  </id_info>
  <brief_title>Omepral速 Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis</brief_title>
  <acronym>OMAREE</acronym>
  <official_title>Omepral速 Tablets Mega-study to Investigate the Efficacy on Various Type of Acid Reflux Related Symptoms and QOL, and Epidemiology in Patients With Erosive Esophagitis in Daily Medical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, non-interventional study is to compare the efficacy of Omepral速 tablet and
      any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various
      type of acid reflux related symptoms in patients with reflux esophagitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients symptom evaluated by investigator</measure>
    <time_frame>at entry, 4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients reported symptom</measure>
    <time_frame>at entry, 4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients reported outcome score</measure>
    <time_frame>at entry, 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10703</enrollment>
  <condition>Reflux Esophagitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients endoscopically diagnosed as erosive esophagitis accompanied with either two days
        or more heartburn or acid taste in the mouth of any severity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients newly diagnosed as erosive esophagitis or history of erosive esophagitis
             confirmed by endoscopy.

          -  Patients who answered questionnaires of quality of life (QOLRAD-J), symptom severity
             and frequency and treatment satisfaction.

          -  During the past 1 week , patients who have either two days or more with heartburn or
             acid taste in the mouth of any severity

        Exclusion Criteria:

          -  Patients receiving treatment with proton pump inhibitors, which make stomach acid
             decreased during the last 4 weeks prior to enrolment.

          -  Patients who cannot answer questionnaires of quality of life (QOLRAD-J), symptom
             severity and frequency and treatment satisfaction.

          -  Patients included previously in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Japan Medical Director MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Huvenne, Alain / Senior Medical Marketing Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Reflux esophagitis</keyword>
  <keyword>Omepral速</keyword>
  <keyword>QOLRAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

